

IL-10-Engineered Human CD4⁺ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism

Grazia Locafaro, Grazia Andolfi, Fabio Russo, Luca Cesana, Antonello Spinelli, Barbara Camisa, Fabio Ciceri, Angelo Lombardo, Attilio Bondanza, Maria Grazia Roncarolo, and Silvia Gregori

Correspondence: gregori.silvia@hsr.it, mg1@stanford.edu

<https://doi.org/10.1016/j.ymthe.2024.02.012>

(Molecular Therapy 25, 2254–2269; October 2017)

In the originally published version of this article, there is an error in Figure 8A, where there is a duplication of the mouse pictures at day 5 and day 7. The error occurred during the editing of Figure 8A and does not affect the overall conclusion of the paper. A corrected version of the figure is provided below.

The authors apologize for this error and any confusion this may have caused.






Figure 8. CD4^{IL-10} Cells Contribute with Allogeneic PBMCs in Mediating GvL while Inhibiting XenoGvHD